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Abstract 
Background 
Human papillomavirus (HPV) vaccination for young women up to age 26 is highly cost-effective 
and has been implemented in 65 countries globally. We investigate the cost-effectiveness for 
HPV vaccination program in older women (age >26 years), heterosexual men and men who have 
sex with men (MSM). 
Method 
A targeted literature review was conducted on PubMed for publications between January 2000 
and January 2017 according to the PRISMA guidelines. We included English-language articles 











women over age 26, heterosexual men, and MSM and identified the underlying factors for its 
cost-effectiveness. 
Results 
We included 36 relevant articles (six, 26 and four in older women, heterosexual men and MSM, 
respectively) from 17 countries (12 high-income (HICs) and five low- and middle-income 
(LMICs) countries). Most (4/6) studies in women over age 26 did not show cost-effectiveness 
($65,000-192,000/QALY gained). Two showed cost-effectiveness, but only when the vaccine 
cost was largely subsidised and protection to non-naïve women was also considered. Sixteen of 
26 studies in heterosexual men were cost-effective (ICER=$19,600-52,800/QALY gained in 
HICs; $49-5,860/QALY gained in LMICs). Nonavalent vaccines, a low vaccine price, fewer 
required doses, and a long vaccine protection period were key drivers for cost-effectiveness. In 
contrast, all four studies on MSM consistently reported cost-effectiveness (ICER=$15,000-
$43,000/QALY gained), particularly in MSM age <40 years and those who were HIV-positive. 
Countries’ vaccination coverage did not significantly correlate with its per-capita Gross National 
Income. 
Conclusion 
Targeted HPV vaccination for MSM should be next priority in HPV prevention after having 
established a solid girls vaccination programme. Vaccination for heterosexual men should be 
considered when 2-dose 4vHPV/9vHPV vaccines become available with a reduced price, 
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Introduction 
Human Papillomavirus (HPV) infection is a common sexually transmitted infection (STI) and a 
necessary cause for cervical cancer in women [1]. It is also responsible for anal, vaginal, vulvar, 
oropharyngeal and penile cancers [2]. Cervical cancer was the fourth most common cancer 
among women globally, and second (only after breast cancer) in women in low- and middle- 
income countries (LMICs) [3]. According to the World Health Organization (WHO), an 
estimated 530,000 cervical cancers were diagnosed in 2012, and approximately 270,000 women 
per year died from cervical cancer worldwide. More than 90% of deaths occur in low- and 
middle- income countries (LMICs) due to poor access to screening and treatment services [4]. 
However, HPV infection is vaccine-preventable, and currently approved vaccines have achieved 
an excellent safety and efficacy profile [5]. 
National HPV vaccination programs have been initiated over a decade ago, but there are large 
disparities in coverage and targeted populations of vaccination strategies between countries 
where the program has been introduced. By mid-2016, national HPV vaccination programs have 
been established in 65 countries globally, most of which are high-income countries (HICs). 
Strong momentum has been observed to expand HPV vaccination programs to LMICs, where the 
majority of HPV-related cancers occur [6]. 
The type of HPV vaccination program that countries choose to implement depends on the 











HPV vaccination programs target 9-14 year old schoolgirls before sexual debut and it is cost-
effective if more than 70% of young women are vaccinated [7]. There remain lots of debate 
around whether it is cost-effective to expand the existing vaccination programs to also include 
women older than 26 years, heterosexual men, and men who have sex with men (MSM). Unlike 
HPV vaccination for adolescent girls and women up to 26 years which has been shown to be 
highly cost-effective in many studies [8-13], relatively fewer cost-effectiveness analyses (CEA) 
on HPV vaccination have been conducted in other population groups. This study aims to 
investigate the cost-effectiveness of HPV vaccination program for women older than 26 years, 
heterosexual men and MSM and the factors that drive its cost-effectiveness through a literature 
review. 
Results 
Study Selection and Characteristics 
A total of 407 published articles were identified through PubMed (Figure 1). Initial screening 
eliminated 14 duplicated articles and a further 253 articles were excluded because they were not 
cost-effectiveness analyses of HPV vaccination. The remaining 140 articles were reviewed in 
full-text for eligibility according to our inclusion and exclusion criteria. Another 104 articles 
were excluded and 36 papers were eventually selected for our literature review. Among these 36 
studies, six reported on women over age 26, 26 on heterosexual men, four on MSM and one 











countries (12 high-income countries (HICs) and five low- and middle- income countries 
(LMICs), Table 1). Most (64%, n=23) selected studies were published in 2011 or later. 
Cost-effectiveness of HPV vaccination for >26-year-old women 
Six studies [14-19] evaluated the cost-effectiveness of 2vHPV vaccine in women >26 years. Four 
studies [14, 15, 17, 19] found the costs for targeted vaccination for women >26 years  (ICER= 
US$65,000-192,000/QALY gained, Table S1) were beyond their respective cost-effectiveness 
thresholds (~$50,000/QALY gained) (Figure 2a). Four studies assumed vaccination cost 
US$283-400/3-dose vaccination schedule and concluded the program as not cost-effective. 
However, one study from the UK [14] showed marginal cost-effectiveness when vaccine price 
was below £20/dose and life-time vaccine protection for women when no loss of immunity over 
time was considered. Another study from Lao PDR [18] showed the program to be cost-effective 
with a catch-up vaccination for women up to age 75 years and the existing schoolgirls 
vaccination program was strongly subsidised by GAVI, the Vaccine Alliance (US$8.5/dose). 
Only one Belgium study [16] demonstrated their program to be very cost-effective with the 
2vHPV for women age up to 33 years (Table S1). Both the Lao PDR and Belgium studies 
assumed high vaccination coverage (≥70%). All studies assumed 3-dose vaccination strategies 
and none compare it with a 2-dose vaccination strategy. 
Cost-effectiveness of HPV Vaccination for Heterosexual men 
Of 26 selected studies [12, 20-43] on gender-neutral vaccination (three in LMICs and 23 in 











Sixteen studies [21-24, 26, 35-45] demonstrated that HPV vaccination for heterosexual men with 
an existing female program was cost-effective (ICER = $19,600-52,800/QALY gained in HICs 
and $49-5,860/QALY gained in LMICs, Table S1) with respect to their respective cost-
effectiveness thresholds (Figure 2a). 
All four studies that assessed 9vHPV [35, 37, 39, 41] vaccine concluded that the vaccine for both 
girls and boys was cost-effective (ICER=$8600-49800/QALY gained, Table S1) in comparison 
with 2vHPV or 4vHPV vaccination for both women and/or men. The majority (2/3) of studies 
with 2vHPV vaccination [23, 29] was not cost-effective, while 11/20 studies with 4vHPV 
vaccination were cost-effective. Interestingly, when stratified by five-year time periods (<2010, 
2010-2014 and ≥2015, Figure 2b), increasing proportion of studies demonstrated cost-
effectiveness of HPV vaccination for heterosexual men in recent years (p-value=0.035). 
The assumed price of HPV vaccines varied substantially across studies (US $10-130/dose), and 
our analysis did not show any correlation between vaccine price and program cost-effectiveness 
in heterosexual men. While 3-dose vaccination strategy showed mixed results (14 cost-effective 
and 11 not), both studies with a 2-dose vaccination strategy showed cost-effectiveness [44, 45]. 
Longer duration of vaccine protection (life time protection) and program evaluation (100 years 
horizon) led to lower ICERs in these studies. 
Age was an important factor for vaccine cost-effectiveness. Eight studies showed it was cost-
effective to expand existing schoolgirl program to cover schoolboys at the same age (<15 years). 
However, a UK study [27] and a Danish study [30] demonstrated that in the presence of a 











option than expanding schoolgirl program to cover the same age schoolboys. Eight studies 
showed that vaccination program for schoolboys and heterosexual men was no longer cost-
effective if the vaccination coverage in women was beyond 70-75%. There was no evidence that 
the countries’ economic development status and vaccine efficacy had any impact on the cost-
effectiveness of vaccination program for heterosexual men. 
Cost-effectiveness of HPV Vaccination for MSM 
Four studies [46-49] evaluated the cost-effectiveness of 4vHPV vaccine for MSM. All four 
studies demonstrated that the 4vHPV vaccine for MSM compared with no vaccination was cost-
effective ($15,000-43,000/QALY gained) (Figure 2 a, Table S1), and it showed lower ICERs, 
hence better cost-effectiveness, for vaccination against MSM at a young age (<40 years) or 
against those who were HIV-positive. A good cost-effectiveness of HPV vaccination for MSM 
was also associated with a high vaccination coverage (at least 55-80%), a potent vaccine efficacy 
(50-90%), a low vaccine price of 4vHPV (US$180-360/3-doses), a long duration of evaluation 
(life-time/100 years’ time horizon) (Table 2). In all MSM studies, there was no evidence that the 
socio-economic development status of the countries and vaccine dosage influenced the cost-
effectiveness of MSM vaccination. 
Vaccination and cervical cancer screening in included countries 
The HPV vaccination and cervical cancer screening programs from the selected studies were 
described in Table 1. The annual cervical cancer incidence was generally higher (9.4-23.7 versus 











rate for cervical cancer (3.4-8.0 versus 1.4-2.1 per 100,000). Cervical cancer mortality rates were 
significantly and negatively correlated with Gross National Income (GNI) (Spearman, r=-0.75, 
p<0.001). Cervical cancer screening coverage among targeted women in HIC was more than 50-
70%. In contrast, among LMIC, only Brazil reached a similar screening coverage as in HIC, 
while other countries were consistently below 40%. All National HPV vaccination programs for 
schoolgirls (up to age 14) were introduced before 2011 in HIC, and some programs included a 
catch-up program for young women up to age 26. To date, Austria, Australia, Canada, and the 
US, have expanded the vaccination program to schoolboys (age 9-14 years). In contrast, HPV 
vaccination began much later in LMICs, typically between 2013 and 2015 and China and 
Vietnam did not implement any vaccination programs until 2017. Vaccination coverage for 
women ranged from 40-80% in developed countries, where Germany had the lowest (40%) and 
the United Kingdom the highest (80%) coverage. We found no significant correlation between 
GNI per capita and vaccination coverage (R=-0.0049, p=0.9877). 
Discussion 
Our targeted literature review indicated that HPV vaccine for women >26 years would not be 
cost-effective, and this is consistent with current policy and practice. In contrast, HPV 
vaccination for heterosexual men demonstrated mixed results: programs proposing 9vHPV 
(compared with 4vHPV and 2vHPV), those assuming a long duration of vaccine effectiveness 
and those vaccinating young heterosexual men (<26) demonstrated cost-effectiveness. Further, it 
suggested that targeted HPV vaccination for MSM is cost-effective in all four included studies. 











girls in LMICs has shown that vaccine price is one of the key determinant of vaccination cost-
effectiveness [50]. Our review further confirms this is also true in heterosexual men and MSM. 
In addition, we also identified a broad genotype coverage (9vHPV), less required doses and 
longer vaccine protection are important determinants for cost-effectiveness. 
Our findings suggests that targeted HPV vaccination for MSM should be a priority worldwide. 
Unlike heterosexual men, MSM may benefit to a lesser extent from the herd immunity that 
heterosexual men may receive from the female vaccination programs [51]. On the other hand, 
MSM are much more at-risk than heterosexual men to HPV infection in particular anogenital 
warts and anal cancer. In contrast to vaccination program in women where the vaccination 
coverage required (~70%) is well established, the vaccination coverage required in MSM to 
achieve the same level of herd immunity that heterosexual men may experience is not known. 
Since the reproductive rate of HPV infection in MSM is much greater than heterosexual men, it 
is likely that a higher level of vaccination coverage will be required [52]. 
Despite only 16 of 26 studies in heterosexual men demonstrating cost effectiveness, our data 
suggest that a gender neutral vaccination strategy may become increasingly cost-effective for a 
number of reasons. First, recent literatures reported that 1- or 2-doses vaccination is as effective 
as 3-doses vaccination for people age 9-14 years, which means a potential 30% cost reduction 
per head if this is implemented in any school age vaccination programs [53-55]. Second, it is 
anticipated that the mean price of HPV vaccine for LMICs will continue to decline over time, 
especially with significant subsidies and influence from major international health organizations 











Our analysis shows no correlation between individual country’s socio-economic status and 
vaccination coverage. However, we argue that the rollout of a universal HPV vaccination 
program in LMICs may face more challenges. Given limited resources, LMICs generally have a 
lower willingness-to-pay threshold for a vaccination program. Therefore, vaccine cost needs to 
be substantially lowered in LMICs, not only for the consideration of cost-effectiveness, but also 
the upfront investment cost must not become an excessive financial burden to the country 
budget. The initial rollout of the program often require a one-time investment for health 
facilities, establishment of an efficient implementation system and training for healthcare staff. 
Further, in resource-poor settings, an efficient healthcare provision system is often absent to 
provide the scheduled vaccination program, which is an essential infrastructure for additional 
HPV vaccination programs. For these settings, resources from the international community 
should be directed to provide point-of-care vaccination where primary healthcare is absent, and 
2-dose HPV vaccine should be promoted to improve vaccination coverage in the population. 
A number of limitations need to be considered when interpreting our results. As a targeted 
literature review, we excluded studies not published in English and therefore, our study may be 
subject to publication bias. Second, we could not conduct a meta-analysis due to limited data 
available from targeted reviews. Similarly, we could not prove the robustness of outcomes 
because of the variations in models applied in the included studies where different assumptions 
and parameters were used. For instance, population impact was not reported in a consistent form 
across the studies, however, we emphasized that all cost-effectiveness studies included a baseline 
scenario and the analysis was conducted by comparing the scenarios in the presence and absence 











the cost-effectiveness instead. Despite these limitations, we believe our findings would be a 
springboard for further studies of the cost-effectiveness of HPV vaccination for these currently 
untargeted populations. 
Conclusion 
Targeted HPV vaccination for MSM should be next priority in HPV prevention after having 
established a solid girls vaccination programme. Vaccination for heterosexual men should be 
considered when 2-dose 4vHPV/9vHPV vaccines become available with a reduced price. 




The full electronic search was conducted in PubMed for related articles and reviews on February 
15th 2017, which were published in the English language from January 1, 2000 to December 31, 
2016. The search strategy was conducted using the following key words: “Human 
Papillomavirus” AND “Cost-effectiveness” AND “Vacc*” in MeSH terms AND “HPV” OR 
“Human Papillomavirus” AND “Cost-effective*” AND “Vacc*” in titles and abstracts AND 












This review included English-language articles (published between 2000-2016) that assessed the 
incremental cost-effectiveness ratio (ICER) of HPV vaccination to the female population older 
than 26 years, heterosexual men and MSM, in comparison with the cost-effectiveness of existing 
cervical cancer screening or vaccination in young adolescent girls with a catch-up program for 
women age up to 26 years. In this review, the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses) statement [58] was followed (Figure 1). Articles were 
excluded if they (1) were in a language other than English; (2) did not report ICER of the HPV 
vaccination program; and (3) only focused on young female vaccination program. 
Data collection 
We collected demographic data, HPV epidemiological data, impact and cost-effectiveness data 
from aforementioned literature review. In addition, based on the countries identified from the 
selected studies, we further collected data on country-specific HPV-related programs and country 
incomes that were not available in the literature research. 
First, demographic data included age and sex of the targeted population, period of analysis 
(retrospective or prospective study) and country of the study population. Second, 
epidemiological data included status quo HPV disease burden, subtypes and vaccination 
coverage. Third, population impact data included the type of model used, reduction in HPV 











cancer cases and mortality. Fourth, cost-effectiveness data included incremental cost associated 
with HPV vaccination programs; incremental cost-effectiveness ratios (ICERs); incremental life-
years gained (LYGs) or Quality-adjusted life-years (QALYs) gained from a vaccination 
program. Fifth, we identified 17 countries from the selected 36 publications. For these 17 
countries, we collected other HPV-related program and income data from these well-known 
online HPV databases: HPV Information Centre [59]; National Cancer Institute [60]; and 
International Agency for Research on Cancer [61]. Specific country data included: gross 
National Income per capita (GNI); age-standardized incidence rate of cervical cancer; age-
standardized mortality rate of cervical cancer; existence of national cervical cancer screening and 
HPV vaccination programs; years of introduction of the national HPV vaccination program; 
targeted age and gender of current HPV vaccination program; vaccination coverage; and cervical 
cancer screening coverage. Double-entry was performed to extract these data by two independent 
investigators (NNS, FC). Microsoft excel 2013 was used to store and analyse these data. 
Quality Assessment 
The quality assessment of each included study was conducted by two independent investigators 
(NNS, FC). Any conflicting opinions were resolved by a third reviewer (LZ). The quality check 
for each included study was assessed by three domains: study design, data collection, and 













Descriptive statistics were conducted for each study population group (older women, 
heterosexual men and MSM) to inform HPV program, impact and cost-effectiveness indicators. 
First, for each population, we categorized the selected studies that showed proposed strategy was 
cost-effective according to their stated willingness-to-pay threshold, and those showed it was not 
cost-effective. Second, the major contributing factors influencing the cost-effectiveness, 
including vaccination age and coverage, vaccine efficacy, price and dosage, duration of vaccine 
protection, and the time horizon of evaluation, were identified in both cost-effective and non-
cost-effective studies. A Spearman’s correlation test was used to analyse the correlation between 
the GNI and HPV-burden of the included countries. In addition, chi-square tests were conducted 
to investigate the time trend of cost-effectiveness of HPV vaccination for heterosexual males. 
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Table 1. Summary table of key cost-effectiveness indicators from 36 included publications 














































































































































































































































































































































































































































































































































































































































































































































































































































































































MSM=Men-who-have-sex-with-men; GM=Heterosexual men; GF=Women; FM=Males and women; CU=Catch-up; DR=Discounted rate; 
VE=Vaccine efficacy; yr=years; NoVac=No vaccination; HR=Hazard ratio; 2vHPV=Bi-valent vaccine; 4vHPV=Quadri-valent vaccine; 9vHPV=Nona-
valent vaccine; ANA=Anal cancer; GW=Genital warts; CC=Cervical Cancer; CIN=Cervical intraepithelial neoplasia; QALY=Quality-adjusted life 
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3% DR 49,796 (15,947 
CC, 4,912
mortality). 
MSM=Men-who-have-sex-with-men; GM=Heterosexual men; GF=Women; FM=Males and women; CU=Catch-up; DR=Discounted rate; VE=Vaccine efficacy; yr=years; NoVac=N
vaccine; 9vHPV=Nona-valent vaccine; ANA=Anal cancer; GW=Genital warts; CC=Cervical Cancer; CIN=Cervical intraepithelial neoplasia; QALY=Quality-adjusted life year; LYG=L









































































































































































Table 2. Cost-effectiveness study quality checklist 
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